BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/15/2018 7:28:22 AM | Browse: 351 | Download: 163
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 38197
Country/Territory United States
2018-02-05 08:14
Peer-Review Started
2018-02-07 02:52
To Make the First Decision
2018-03-02 00:38
Return for Revision
2018-03-08 01:21
2018-03-14 03:42
Second Decision
2018-04-10 05:54
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2018-04-11 16:57
Articles in Press
2018-04-11 16:57
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2018-05-08 05:43
Publish the Manuscript Online
2018-05-15 07:28
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Merly Contratto and Jennifer Wu
Author(s) ORCID Number
Merly Contratto http://orcid.org/0000-0003-0528-0788
Jennifer Wu http://orcid.org/0000-0002-1714-0021
Funding Agency and Grant Number
Corresponding author Jennifer Wu, MD, Attending Doctor, Associate Professor, Division of Hematology and Oncology, Perlmutter Cancer Center, New York University School of Medicine, 462 First Ave, BCD556, New York, NY10016, United States. jennifer.wu@nyumc.org
Keywords Sequencing treatment; Sorafenib; Hepatocellular carcinoma treatments; Nivolumab; Regorafenib; Lenvatinib; Cabozantinib; Immunotherapy; Biomarker; Pembrolizumab; Ramucirumab; Alpha-fetoprotein; Neoantigen; Tumor mutational burden; Interferon-gamma
Core Tip Hepatocellular carcinoma (HCC) is the fifth leading cause of cancer mortality in the United States and the second leading cause of cancer mortality worldwide. There are some potential treatment options for first and second line HCC, there are also new biomarkers that can predict benefits from treatments such as immune checkpoint inhibitors.
Publish Date 2018-05-15 07:28
Citation Contratto M, Wu J. Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. World J Gastrointest Oncol 2018; 10(5): 108-114
Url http://www.wjgnet.com/1948-5204/full/v10/i5/108.htm
DOI http://dx.doi.org/10.4251/wjgo.v10.i5.108
Full Article (PDF) WJGO-10-108.pdf
Full Article (Word) WJGO-10-108.doc
Manuscript File 38197-Review.docx
Answering Reviewers 38197-Answering reviewers.pdf
Audio Core Tip 38197-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 38197-Conflict-of-interest statement.pdf
Copyright License Agreement 38197-Copyright assignment.pdf
Peer-review Report 38197-Peer-review(s).pdf
Scientific Editor Work List 38197-Scientific editor work list.pdf